Raymond James & Associates grew its position in Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) by 45.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,068,387 shares of the company's stock after purchasing an additional 642,161 shares during the period. Raymond James & Associates owned about 4.90% of Foghorn Therapeutics worth $13,341,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in FHTX. Tower Research Capital LLC TRC lifted its position in Foghorn Therapeutics by 300.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,921 shares of the company's stock worth $25,000 after buying an additional 3,692 shares in the last quarter. UBS Group AG acquired a new position in Foghorn Therapeutics during the 4th quarter worth about $32,000. Wells Fargo & Company MN lifted its position in Foghorn Therapeutics by 1,368.4% during the 4th quarter. Wells Fargo & Company MN now owns 5,389 shares of the company's stock worth $34,000 after buying an additional 5,022 shares in the last quarter. Barclays PLC lifted its position in Foghorn Therapeutics by 533.5% during the 4th quarter. Barclays PLC now owns 5,397 shares of the company's stock worth $34,000 after buying an additional 4,545 shares in the last quarter. Finally, Citigroup Inc. lifted its position in Foghorn Therapeutics by 1,321.0% during the 2nd quarter. Citigroup Inc. now owns 6,778 shares of the company's stock worth $48,000 after buying an additional 6,301 shares in the last quarter. Institutional investors and hedge funds own 61.55% of the company's stock.
Foghorn Therapeutics Trading Down 2.2 %
NASDAQ FHTX traded down $0.16 on Thursday, hitting $7.05. 93,886 shares of the company were exchanged, compared to its average volume of 163,749. The firm has a 50 day moving average of $5.95 and a two-hundred day moving average of $5.09. The company has a market cap of $300.12 million, a P/E ratio of -3.01 and a beta of 3.13. Foghorn Therapeutics Inc. has a 1-year low of $2.70 and a 1-year high of $9.97.
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.22. The company had revenue of $5.77 million for the quarter, compared to analyst estimates of $4.91 million. Research analysts anticipate that Foghorn Therapeutics Inc. will post -2.05 EPS for the current fiscal year.
Foghorn Therapeutics Company Profile
(
Free Report)
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Read More
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
